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ABSTRACT
Objectives To assess the compliance of Asian intensive
care units and hospitals to the Surviving Sepsis
Campaign’s resuscitation and management bundles.
Secondary objectives were to evaluate the impact of
compliance on mortality and the organisational
characteristics of hospitals that were associated with
higher compliance.
Design Prospective cohort study.
Setting 150 intensive care units in 16 Asian countries.
Participants 1285 adult patients with severe sepsis
admitted to these intensive care units in July 2009. The
organisationalcharacteristicsofparticipatingcentres,the
patients’ baseline characteristics, the achievement of
targets within the resuscitation and management
bundles, and outcome data were recorded.
Main outcome measure Compliance with the Surviving
Sepsis Campaign’s resuscitation (six hours) and
management (24 hours) bundles.
Results Hospital mortality was 44.5% (572/1285).
Compliance rates for the resuscitation and management
bundles were 7.6% (98/1285) and 3.5% (45/1285),
respectively. On logistic regression analysis, compliance
with the following bundle targets independently
predicted decreased mortality: blood cultures (achieved
in 803/1285; 62.5%, 95% confidence interval 59.8% to
65.1%), broad spectrum antibiotics (achieved in 821/
1285; 63.9%, 61.3% to 66.5%), and central venous
pressure(achievedin345/870;39.7%,36.4%to42.9%).
High income countries, university hospitals, intensive
care units with an accredited fellowship programme, and
surgical intensive care units were more likely to be
compliant with the resuscitation bundle.
Conclusions While mortality from severe sepsis is high,
compliance with resuscitation and management bundles
is generally poor in much of Asia. As the centres included
in this study might not be fully representative,
achievement rates reported might overestimate the true
degreeofcompliancewithrecommendedcareandshould
be interpreted with caution. Achievement of targets for
blood cultures, antibiotics, and central venous pressure
was independently associated with improved survival.
INTRODUCTION
Severe sepsis is a prevalent, costly, and often fatal
condition.
12 To improve outcomes in severe sepsis,
the Surviving Sepsis Campaign recommends a six
hour resuscitation bundle,
3 including early blood cul-
tures and antibiotics
4 and various aspects of early goal
directedtreatmentfor haemodynamic derangements.
5
A 24 hour management bundle is also recommended,
which includes low dose steroids,
6 drotrecogin alfa
(activated),
7 glucose control,
8 and guidelines on venti-
latory support.
9 Several single and multicentre studies
and a meta-analysis have suggested that compliance
with these recommendations can benefit survival.
10-17
Whether Asian intensive care units and emergency
departments follow the sepsis bundles is unknown.
Adherence to guidelines is often poor.
18 National
efforts to promote the Surviving Sepsis Campaign
guidelinesdonotexistinmostofAsia,wherecostcon-
cerns limit the ability to implement potentially expen-
sive bundles,
1920 and, at least in some countries,
intensive care is underdeveloped.
21 To complicate
matters, several papers have questioned the purported
benefits of the recommended interventions,
22-24 and
recently revised Surviving Sepsis Campaign guide-
lines have toned down the recommendations for ster-
oids, drotrecogin alfa, and glucose control.
2526
With the above considerations in mind, we assessed
compliance of Asian intensive care units and hospitals
withtherecommendationswithintheresuscitationand
managementbundles.Wealsoevaluatedtheimpactof
compliance on mortality and the organisational char-
acteristics of Asian hospitals that were associated with
higher compliance.
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Study design
The Management Of Severe sepsis in Asia’s Intensive
Care unitS (MOSAICS) study is a multinational pro-
spective cohort study. A steering committee of coordi-
nators from various Asian countries, formed in
February 2009, invited physicians representing inten-
sive care units in their countries to participate through
direct contact, circulated emails, and local meetings.
Although participation was voluntary and unfunded,
coordinators were encouraged to include as many
intensive care units as possible to minimise selection
bias.
Participating intensive care units had at least six
beds. They could be medical (including respiratory),
surgical, or mixed, but not predominantly paediatric,
neurosurgical, or coronary intensive care units. All
patients admitted to participating units in July 2009
were screened for eligibility; there was no formal sam-
ple size calculation. We enrolled all adult patients with
severe sepsis, excluding those aged under 21, transfers
from another intensive care unit or hospital, and read-
missions to the intensive care unit during the current
hospital stay. We included patients regardless of
whether they developed severe sepsis or septic shock
before admission to the unit or during their stay. The
definition of severe sepsis was adapted from the 2001
International Sepsis Definitions Conference and the
Surviving Sepsis Campaign
327—that is, sepsis with
the following organ dysfunctions: hypotension (systo-
lic blood pressure <90 mm Hg or a decrease of
>40 mm Hg or mean arterial pressure <65 mm Hg),
hyperlactataemia(≥2mmol/L),renal(acuteincreasein
serum creatinine concentration to >176.8 mmol/L or
urine output <0.5 mL/kg/hour for >2 hours), lung
(acute lung injury with the ratio of the partial pressure
of arterial oxygen to the fractional inspired oxygen
being ≤300 mm Hg), liver (acute increase in bilirubin
concentration to >34.2 μmol/L), thrombocytopenia
(acutedecreaseto<100000/µL),and/orcoagulopathy
(internationalnormalisedratio>1.5orapartialthrom-
boplastin time >60 s).
Data collection
To minimise behavioural change resulting from the
study, only the physicians representing each intensive
care unit were familiarised with the study design, and
no attempts were made to educate the participating
centres on the sepsis bundles. Depending on the avail-
abilityofstaffateachintensivecareunit,eitherclinical
orresearchstaffentereddataontwoonlinedatacollec-
tionforms.Thefirstform,completedbeforeenrolment
of patients, recorded organisational characteristics,
including the type of intensive care unit (open or
closed), specialty (medical, surgical, mixed), number
of beds, 24 hour intensivist cover, number of intensi-
vists, ratio of nurses to beds, any accredited intensive
care fellowship programme, type of hospital (govern-
ment non-university, private non-university, univer-
sity), number of hospital beds, and the country. Data
onthefacilities,equipment,andprotocolsin theinten-
sive care units and their affiliated emergency depart-
ments to facilitate the bundles were also collected.
We defined an intensivist as a physician who has
passed intensive care certification examinations or
who has completed training in an accredited intensive
carefellowshiporwhotreatsthetotalpatientandnota
single organ system and is recognised by his or her
institution as an intensivist.
The second form collected data on patients, includ-
ing demographics (age and sex), type of diagnosis
(medical, scheduled, or unscheduled postoperative),
location of patient at diagnosis of severe sepsis (emer-
gencydepartment,ward,intensivecareunit),sourceof
infection,organdysfunction,numberoforganfailures,
the acute physiology and chronic health evaluation
(APACHE) II score, mortality in intensive care unit
and hospital, length of stay in intensive care unit and
hospital, and duration of invasive mechanical ventila-
tion (time from starting ventilation to successful
Table 1 |Surviving Sepsis Campaign targets considered in study of patients admitted to Asian intensive care units
Target Applicable to relevant clinical scenarios
Resuscitation bundle (first 6 hours)
Measure lactate All patients
Blood cultures before antibiotics All patients
Broad spectrum antibiotics within 3 hours for emergency department
admissions and 1 hour for others
All patients
Fluids (20 mL/kg of crystalloids or equivalent) with or without
vasopressors
Hypotension or lactate ≥4 mmol/L (fluids required) with or without septic
shock (hypotension despite initial fluids: vasopressors required)
CVP ≥8 mm Hg Septic shock or lactate ≥4m m o l / L
ScvO2 ≥70% or SvO2 ≥65% Septic shock or lactate ≥4m m o l / L
Management bundle (first 24 hours)
Low dose steroids administered or considered Septic shock
Drotrecogin alfa (activated) administered or considered APACHE II ≥25 or multiorgan failure
Glucose ≥4.5 and ≤10.0 mmol/L at 6-24 hours All patients
Tidal volume ≤6 mL/kg predicted body weight ALI/ARDS
ALI=acute lung injury; APACHE=acute physiology and chronic health evaluation; ARDS=acute respiratory distress syndrome; CVP=central venous
pressure; ScvO2=central venous oxygen saturation; SvO2=mixed venous oxygen saturation.
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a continuous period of ≥48 hours). This form also
recorded, when clinically appropriate, the achieve-
mentoftargetsinboththeresuscitationbundle(lactate
measurement, blood cultures, broad spectrum anti-
biotics, fluids with or without vasopressors, central
venous pressure, and central or mixed venous oxygen
saturation within six hours after presentation) and the
management bundle (steroids, drotrecogin alfa, glu-
cose control, lung protective ventilation within 24
hours) (table 1). The time of presentation, determined
from chart review,was definedasthe time of presenta-
tion to the emergency department with severe sepsis,
or the time of diagnosis of severe sepsis for patients
who developed severe sepsis in the ward (and other
non-emergency department units) or intensive care
unit.Giventheongoingcontroversyregardingtheeffi-
cacy of steroids and drotrecogin alfa and in line with
the definitions of the Surviving Sepsis Campaign,
311
the targets for these drugs were deemed as met if they
were administered or if there was documentation of
any discussion that showed that they were considered
in the appropriate clinical setting in accordance with
the local intensive care unit policy. We set the upper
limit for glucose at 10.0 mmol/L based on the Normo-
glycaemia in Intensive Care Evaluation and Survival
Using Glucose Algorithm Regulation (NICE-
SUGAR) study and the latest recommendations from
theSurvivingSepsisCampaign,
2426andthelowerlimit
at4.5mmol/LaccordingtovandenBergheetal’spro-
tocol and in view of the adverse effects of
hypoglycaemia.
8 The glucose target was considered
met if all measurements fell within this range. Because
ofconcernsregardingthefeasibilityofaccurateplateau
pressuremeasurementsinpatientswithoutapnoea,we
considered the target for acute lung injury/acute
respiratory distress syndrome, defined according to
the American-European Consensus Conference,
28 as
beingmetifthemostfrequentlydeliveredtidalvolume
was≤6mLperkgofpredictedbodyweight.
9Failureto
achieve a target might be because of failure to attempt
measurements, or might occur even when attempts
were made.
Astheonlinedatacollectionformsweredesignedto
prohibit uncompleted fields, there were no missing
data. We did, however, check the collected data for
statistical outliers that might suggest entry errors and
contacted the intensive care unit representatives for
clarification.
Outcome measures
All patients were followed until discharge from or
death in the hospital. The primary outcome measure
was compliance with the resuscitation and manage-
ment bundles. The secondary outcome measure was
all cause hospital mortality. Patients who were still in
the same hospital on 31 July 2010 (one year from the
end of the enrolment period) were deemed survivors.
Patients who were discharged home in a terminal state
and expected to die within a few hours or days were
deemed non-survivors.
29
Statistical analyses
Categorical variablesare givenasnumber(percentage
and 95% confidence interval for compliance with bun-
dle targets), normally distributed numerical variables
as mean (standard deviation), and other numerical
variables as median (interquartile range). Categorical
variables were analysed with χ
2 test or Fisher’s exact
test. When normality and homogeneity assumptions
were satisfied, quantitative variables were compared
Table 2 |Distribution of participating intensive care units and
patients by country in study of compliance with Surviving
Sepsis Campaign targets
World Bank
analytical income
classification
No of
units
No of enrolled
patients with
severe sepsis
% of all
admissions in
participatingunits
Low income economies:
Bangladesh 14 65 10.8
Nepal 2 62 53.9
Vietnam 3 49 10.7
Middle income economies:
China 40 189 9.1
Indonesia 7 33 6.3
India 17 162 5.5
Malaysia 10 120 15.7
Pakistan 3 36 28.3
High income economies:
Bahrain 1 11 21.2
Brunei 1 12 15.2
Hong Kong 6 102 17.5
Japan 1 3 8.8
Saudi Arabia 5 46 12.5
Singapore 10 128 25.2
South Korea 28 254 10.4
Taiwan 2 13 15.3
Total 150 1285 10.9
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Fig 1 | Compliance with resuscitation and management
bundles by country. Only countries that enrolled more than
100 patients are shown. Others include Bahrain, Bangladesh,
Brunei, Indonesia, Japan, Nepal, Pakistan, Saudi Arabia,
Taiwan, and Vietnam. Drotrecogin alfa was unavailable in nine
countries, including China, Hong Kong, and South Korea
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used. The Bonferroni correction was used for pairwise
comparisons.
Wecomparedpatients’characteristics,achievement
of bundle targets, and organisational characteristics of
the managing centres in survivors versus non-survi-
vors. We evaluated organisational characteristics that
were associated with greater compliance with the bun-
dles.WeincludedtheWorldBank’sanalyticalincome
classification from 2009, categorising countries into
low (Bangladesh, Nepal, Vietnam), middle (China,
Indonesia, India, Malaysia, Pakistan), and high (Bah-
rain, Brunei, Hong Kong, Japan, Saudi Arabia, Singa-
pore, South Korea, Taiwan) income economies
30; for
this study we classified China, Hong Kong, and Tai-
wan as different countries given their different eco-
nomic status and healthcare systems. We compared
compliance with the bundles in countries from differ-
entincomeclassificationsandincentreswithandwith-
out management protocols.
In assessing achievements for each target, we
included only patients with relevant clinical scenarios
(table 1). We defined overall compliance with the
entire resuscitation and management bundles when
all relevant individual targets were met. To identify
theindependentpredictorsofmortality,weperformed
multivariable logistic regression analysis using models
thatincludedtheachievementofindividualbundletar-
gets andall the variablescollected forpatients’ charac-
teristics and organisational characteristics, including
the World Bank income classification. We reduced
the sources of infection into lung and non-lung to
decreasethenumberofcovariates.Thefirstregression
model assessed targets required for all patients (lactate
measurement,bloodcultures,antibiotics,glucosecon-
trol) and organisational and patient characteristics.
Other targets, which were required in some but not
all patients—for instance, fluids with or without vaso-
pressors, central venous pressure, central or mixed
venous oxygen saturation, steroids, drotrecogin alfa,
and tidal volumes (table 1)—were assessed with sepa-
rate models for each subpopulation. In each model,
covariates were classified into target met, target not
met, and target not required, as appropriate. We
looked for multicollinearity, as well as interactions
between bundle targets that were independent predic-
torsofmortality bypairingthesetargetsinthe models.
Model fit was assessed with the Hosmer-Lemeshow
goodness of fit test.
We considered a P value of <0.05 as significant. We
usedPASWStatistics,version18.0(SPSS,Chicago,IL,
USA).
Table 3 |Baseline characteristics of patients admitted to intensive care units (ICU) in Asia.
Figures are numbers (percentages) unless stated otherwise
Characteristic
All
(n=1285)
Survivors
(n=713)
Non-survivors
(n=572) Pvalue
Demographics
Mean (SD) age (years) 59.2 (17.8) 57.8 (17.8) 61.0 (17.5) 0.001
Male 793 (61.7) 428 (60.0) 365 (63.8) 0.17
Diagnosis on admission to ICU:
Medical/non-operative 980 (76.3) 543 (76.2) 437 (76.4)
0.95 Scheduled/elective postoperative 90 (7.0) 49 (6.9) 41 (7.2)
Unscheduled/emergent postoperative 215 (16.7) 121 (17.0) 94 (16.4)
Location at diagnosis of severe sepsis:
Emergency department 490 (38.1) 311 (43.6) 179 (31.3)
<0.001* Ward 472 (36.7) 244 (34.2) 228 (39.9)
ICU 323 (25.1) 158 (22.2) 165 (28.8)
Source of infection:
Pneumonia/lung 480 (37.4) 273 (38.3) 207 (36.2)
0.001
Abdomen other than urinary tract 271 (21.1) 156 (21.9) 115 (20.1)
Urinary tract 109 (8.5) 81 (11.4) 28 (4.9)
Soft tissue/skin 57 (4.4) 28 (3.9) 29 (5.1)
Primary bacteraemia 26 (2.0) 13 (1.8) 13 (2.3)
Meningoencephalitis/nervous system 27 (2.1) 11 (1.5) 16 (2.8)
Bones and joints 6 (0.5) 2 (0.3) 4 (0.7)
Intravascular catheter 14 (1.1) 8 (1.1) 6 (1.0)
Infective endocarditis 6 (0.5) 2 (0.3) 4 (0.7)
Multiple sources 223 (17.4) 102 (14.3) 121 (21.2)
Unknown 66 (5.1) 37 (5.2) 29 (5.1)
Organ dysfunction on arrival at ICU:
Hypotension or on vasopressors 939 (73.1) 498 (69.8) 441 (77.1) 0.004
Hyperlactataemia 466 (36.3) 247 (34.6) 219 (38.3) 0.17
Acute kidney injury 528 (41.1) 246 (34.5) 282 (49.3) <0.001
Acute lung injury 665 (51.8) 347 (48.7) 318 (55.6) 0.01
Hyperbilirubinaemia 248 (19.3) 127 (17.8) 121 (21.2) 0.13
Thrombocytopenia 325 (25.3) 151 (21.2) 174 (30.4) <0.001
Coagulopathy 299 (23.3) 139 (19.5) 160 (28.0) <0.001
Mean (SD) No of organ failures 2.7 (1.5) 2.5 (1.3) 3.0 (1.6) <0.001
Mean (SD) APACHE II score 22.8 (8.7) 20.4 (7.7) 25.7 (9.0) <0.001
APACHE II=acute physiology and chronic health evaluation II score during first 24 hours of ICU admission.
*Mortality lower for emergency department patients than for ward patients or ICU patients after Bonferroni
correction.
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Fig 2 | Proportion of emergency departments and intensive
care units with facilities and equipment to perform various
functions. Emergency departments not surveyed for
drotrecogin alfa and glucose measurements. Fibreoptic
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analysers with co-oximetry are required to measure ScvO2
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venous oxygen saturation; SvO2=mixed venous oxygen
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Sixteen countries and 150 intensive care units partici-
pated in the study, enrolling 1285 adult patients
(table 2), which accounted for 10.9% of all intensive
care unit admissions during the study period. There
were 713 survivors: five were still in the same hospital
on31July2010.Atotalof572didnotsurvive:515died
before discharge and 57 were terminally discharged.
The overall hospital mortality was 44.5% (572/1285),
and the intensive care unit mortality was 36.7% (471/
1285). The median (interquartile range) length of stay
intheintensivecareunitandhospitalwas7days(4-12)
and 18 days (11-33), respectively, in survivors and
6 days (3-12) and 10 days (4-22), respectively, in non-
survivors. The duration of mechanical ventilation was
6 days (3-9) in 450 survivors and 4 days (2-10) in 523
non-survivors. Table 3 shows the patients’ baseline
characteristics. The mean APACHE II score was 22.8.
Table 4 records the achievement of bundle targets,
in addition to any attempts to measure central venous
pressure, central or mixed venous oxygen saturation,
and glucose concentration within the stipulated time
frames. The only targets that were achieved more
than 50% of the time were blood cultures, antibiotics,
fluids with or without vasopressors, and steroids
(table 4). Compliance with the entire resuscitation
bundle and management bundle was 7.6% (98/1285)
and 3.5% (45/1285), respectively. Figure 1 shows the
compliance rates of countries that enrolled more than
100 patients. Drotrecogin alfa was unavailable in nine
countries(Bangladesh,China,HongKong,Indonesia,
Japan, Nepal, Pakistan, South Korea, Vietnam); when
itwasexcludedfromthemanagementbundle,compli-
ance increased to 11.6% (149/1285).
Table 5 describes the organisational characteristics
of the participating centres. Countries with a high
income economy, university hospitals, intensive care
units with an accredited fellowship programme, and
surgical intensive care units were more likely to be
compliant with the entire resuscitation bundle. There
Table 4 |Achievement of Surviving Sepsis Campaign bundle targets in Asian intensive care units. Figures are numbers of patients (percentage, 95%
confidence interval), unless specified otherwise
Target All Survivors Non-survivors P value
Resuscitation bundle (first 6 hours)
Measure lactate 511/1285 (39.8, 37.1 to 42.5) 310/713 (43.5, 39.8 to 47.1) 201/572 (35.1, 31.2 to 39.1) 0.002
Blood cultures before antibiotics 803/1285 (62.5, 59.8 to 65.1) 471/713 (66.1, 62.6 to 69.5) 332/572 (58.0, 54.0 to 62.1) 0.004
Broad spectrum antibioticswithin3 hoursfor EDadmissions and
1 hour for others
821/1285 (63.9, 61.3 to 66.5) 478/713 (67.0, 63.6 to 70.5) 343/572 (60.0, 60.0 to 64.0) 0.009
Fluids with or without vasopressors 810/995 (81.4, 79.0 to 83.8) 437/529 (82.6, 79.4 to 85.8) 373/466 (80.0, 76.4 to 83.7) 0.30
Fluids for hypotension/hyperlactataemia 883/995 (88.7, 86.8 to 90.7) 480/529 (90.7, 88.3 to 93.2) 403/466 (86.5, 83.4 to 89.6) 0.03
Vasopressors for persistent hypotension 722/805 (89.7, 87.6 to 91.8) 356/405 (87.9, 84.7 to 91.1) 366/400 (91.5, 88.8 to 94.2) 0.09
CVP ≥8 mm Hg 345/870 (39.7, 36.4 to 42.9) 187/444 (42.1, 37.5 to 46.7) 158/426 (37.1, 32.5 to 41.7) 0.13
ScvO2 ≥70% or SvO2 ≥65% 94/870 (10.8, 8.7 to 12.9) 55/444 (12.4, 9.3 to 15.5) 39/426 (9.2, 6.4 to 11.9) 0.13
Management bundle (first 24 hours)
Low dose steroids considered or administered 449/805 (55.8, 52.4 to 59.2) 211/405 (52.1, 47.2 to 57.0) 238/400 (59.5, 54.7 to 64.3) 0.04
Drotrecogin alfa considered or administered:
In all countries 34/1052 (3.2, 2.2 to 4.3) 23/559 (4.1, 2.5 to 5.8) 11/493 (2.2, 0.9 to 3.5) 0.09
Only in countries with drug 34/411 (8.3, 5.6 to 10.9) 23/210 (11.0, 6.7 to 15.2) 11/201 (5.5, 2.3 to 8.6) 0.04
Glucose ≥4.5 and ≤10.0 mmol/L at 6-24 hours 348/1285 (27.1, 24.7 to 29.5) 213/713 (29.9, 26.5 to 33.2) 135/572 (23.6, 20.1 to 27.1) 0.01
Tidal volume ≤6 mL/kg PBW 74/630 (11.7, 9.2 to 14.3) 35/281 (12.5, 8.6 to 16.3) 39/349 (11.2, 7.9 to 14.5) 0.62
Overall compliance
Entire resuscitation bundle 98/1285 (7.6, 6.2 to 9.1) 74/713 (10.4, 8.1 to 12.6) 24/572 (4.2, 2.6 to 5.8) <0.001
Entire management bundle 45/1285 (3.5, 2.5 to 4.5) 33/708 (4.6, 3.1 to 6.2) 12/572 (2.1, 0.9 to 3.3) 0.01
Entire management bundle without factoring in drotrecogin alfa 149/1285 (11.6, 9.9 to 13.4) 102/713 (14.3, 11.7 to 16.9) 47/572 (8.2, 6.0 to 10.5) 0.001
Median (interquartile range) minutes from diagnosis of severe sepsis to*:
Measure lactate 147 (36 to 390) 130 (30 to 336) 180 (43 to 432) 0.002
Blood cultures 89 (30 to 193) 80 (30-189) 99 (31 to 205) 0.003
Broad spectrum antibiotics 130 (60 to 275) 120 (60 to 240) 150 (62 to 310) 0.009
CVP ≥8 mm Hg 295 (120 to 540) 255 (90 to to 488) 310 (140 to 588) 0.01
ScvO2 ≥70% or SvO2 ≥65% 370 (152 to 718) 360 (172 to 721) 370 (140 to 710) 0.74
Other measures†:
CVP measured in first 6 hours 601/870 (69.1, 66.0 to 72.2) 310/444 (69.8, 65.6 to 74.1) 291/426 (68.3, 63.9 to 72.7) 0.63
ScvO2 or SvO2 measured in first 6 hours 213/870 (24.5, 21.6 to 27.3) 117/444 (26.4, 22.3 to 30.5) 96/426 (22.5, 18.6 to 26.5) 0.91
Low dose steroids administered in first 24 hours 322/805 (40.0, 36.6 to 43.4) 138/405 (34.1, 29.5 to 38.7) 184/400 (46.0, 41.1 to 50.9) 0.001
Drotrecogin alfa administered in first 24 hours 3/1052 (0.3, 0 to 0.6) 1/559 (0.2, 0 to 0.5) 2/493 (0.4, 0 to 1.0) 0.60
Glucose measured at 6-24 hours 1216/1285 (94.6, 93.4 to 95.9) 678/713 (95.1, 93.5 to 96.7) 538/572 (94.1, 92.1 to 96.0) 0.41
CVP=central venous pressure; ED=emergency department; PBW=predicted body weight; ScvO2=central venous oxygen saturation; SvO2=mixed venous oxygen saturation.
*Time from diagnosis of severe sepsis to achievement of bundle targets recorded only if targets achieved within 24 hours.
†Data for CVP, ScvO2 and SvO2, and glucose refer to presence of measurements within stipulated time frames regardless of whether clinical targets achieved.
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tics and compliance with the entire management bun-
dle. Table 6 shows the achievement of targets within
the resuscitation and management bundles, stratified
by the World Bank income classification.
On univariable analysis, meeting the targets for lac-
tate measurement, blood cultures, antibiotics, and glu-
cose control was associated with decreased mortality;
meeting the target for low dose steroids was associated
with increased mortality (table 4). Organisational fac-
tors associated with reduced mortality were high
income country, intensive care unit with an accredited
fellowship programme, intensive care unit with more
than 20 beds, and surgical intensive care unit. Treat-
ment in a government non-university hospital was
associated with increased mortality (table 5).
On logistic regression analysis, with models that
included the achievement of individual bundle targets
and all variables in tables 3 and 5, the independent
predictors of decreased mortality were the achieve-
ment of the bundle targets for blood cultures and anti-
biotics and lower age, lower APACHE II score, and
being diagnosed with severe sepsis in the emergency
department (table 7). There was no interaction
between these targets and no multicollinearity, and
the logistic regression models fit well.
Figure 2 shows the proportion of centres with the
facilities and equipment available to support the bun-
dles. Many could not measure lactate and central or
mixed venous oxygen saturation (using either co-oxi-
metry or dedicated fibreoptic catheters) and did not
haveaccesstodrotrecoginalfa.Figure3showstheexis-
tence of management protocols. The presence of such
protocolsintheintensivecareunitswasassociatedwith
a greater achievement of the targets for lactate mea-
surement, central or mixed venous oxygen saturation,
steroids, and drotrecogin alfa (fig 4).
DISCUSSION
Principal findings
In the Asian centres studied, the overall compliance
with the Surviving Sepsis Campaign resuscitation and
managementbundleswas7.6%and3.5%,respectively.
Compliance was considerably higher, but still incom-
plete, for those components of the bundles that were
independently associated with reduced mortality:
blood cultures (62.5%), broad spectrum antibiotics
(63.9%), and central venous pressure ≥8m mH g
(39.7%). High income countries, university hospitals,
intensive care units with an accredited fellowship pro-
gramme, and surgical intensive care units were more
likely to comply with the resuscitation bundle.
Study strengths and limitations
The MOSAICS study, a large multinational study of
Asian intensive care units, represents a first step
towards collaborative Asian intensive care research.
To make the study more representative we included a
large number of participating centres, though because
of a lack of funding this resulted in a need for compro-
mise.
Our study is subject to selection bias and might not
fully reflect intensive care throughout Asia. In the
absence of Asian or national registries of intensive
care units to allow systematic recruitment of units we
used a snowball method to identify suitable units,
which might have led to the selection of centres with
a greater interest in sepsis management. Although we
sought to minimise behavioural change in these
Table 5 |Organisational characteristics in Asian intensive care units (ICU) in study of
Surviving Sepsis Campaign targets
Characteristic
No (%)
of ICUs
No (%)
of patients
Compliance with
entire resuscitation
bundle*
Hospital
mortality (%)
% Pvalue† % P value‡
Type of ICU:
Open 60 (40.0) 545 (42.4) 8.4%
0.35
42.4%
0.19
Closed 90 (60.0) 740 (57.6) 7.0% 46.1%
ICU specialty:
Medical 33 (22.0) 376 (29.3) 11.7%
<0.0001
39.4%
<0.001 Surgical 14 (9.3) 85 (6.6) 18.8%§ 29.4%§
Mixed 103 (68.7) 824 (64.1) 4.6% 48.4%
No of ICU beds:
1-10 33 (22.0) 250 (19.5) 6.4%
0.32
46.8%
0.04 11-20 74 (49.3) 623 (48.5) 7.1% 47.0%
≥21 43 (28.7) 412 (32.1) 9.2% 39.3%§
No of intensivists¶:
0-3 58 (38.7) 501 (39.0) 8.4%
0.55
47.7%
0.18 4-6 42 (28.0) 340 (26.5) 7.9% 42.4%
≥7 50 (33.3) 444 (34.6) 6.5% 42.6%
Intensivist cover:
No 24 hour cover 51 (34.0) 429 (33.4) 8.4%
0.46
46.4%
0.34
24 hour cover 99 (66.0) 856 (66.6) 7.2% 43.6%
Nurse-to-bed ratio in each shift:
1 nurse:≥3 beds 25 (16.7) 161 (12.5) 8.1%
0.27
41.0%
0.28 1 nurse:2 beds 65 (43.3) 674 (52.5) 8.6% 43.5%
≥1 nurse:1 bed 60 (40.0) 450 (35.0) 6.0% 47.3%
ICU fellowship programme:
No accredited programme 58 (38.7) 426 (33.2) 5.2%
0.019
50.0%
0.005
Accredited programme 92 (61.3) 859 (66.8) 8.8% 41.8%
Type of hospital:
Government non-
university
46 (30.7) 401 (31.2) 5.2%
0.010
50.9%§
0.008 Private non-university 30 (20.0) 229 (17.8) 6.6% 42.4%
University 74 (49.3) 655 (51.0) 9.5%§ 41.4%
No of hospital beds:
1-500 38 (25.3) 303 (23.6) 5.6%
0.23
43.9%
0.04 501-1000 60 (40.0) 502 (39.1) 7.6% 48.6%
≥1001 52 (34.7) 480 (37.4) 9.0% 40.6%
Country according to 2009 World Bank economy:
Low income 19 (12.7) 176 (13.7) 2.3%
0.002
46.6%
0.001 Middle income 77 (51.3) 540 (42.0) 6.9% 50.0%
High income 54 (36.0) 569 (44.3) 10.0%§ 38.7%§
*Shows only associations with compliance with entire resuscitation because there were no associations with
compliance with entire management bundle.
†P value for association between each organisational characteristic and compliance with entire resuscitation
bundle.
‡P value for association between each organisational characteristic and hospital mortality.
§Applies only to variables with three categories; denotes category that is significantly different compared with
grouping of other two categories (after Bonferroni correction).
¶Refers to number of intensivists in centre who cover ICU, including on rotational basis.
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physicians with in depth knowledge of the study
design, we cannot exclude the presence of a
Hawthorne effect. While there was a good representa-
tion of countries across the World Bank income
categories,
30 intensive care units with less than six
beds were excluded, many of the United Nations’
Least Developed Countries did not participate,
31 and
university hospitals accounted for 50% of centres. The
latter two points stand out when one considers the fact
that all participating units could perform blood cul-
tures, measure central venous pressure, arterial blood
gases, glucose, and carry out the necessary chemical
analyses to calculate the APACHE II score, all of
which are a relative luxury in the most resource poor
areas in Asia. Importantly, the number of patients in
the study sample was not proportionate to the popula-
tion of the countries taking part in the study. About
three quarters of the patients were enrolled in six of
the 16 countries. While some of these countries have
large populations (such as China and India), others
(such as Hong Kong and Singapore) have relatively
small populations, and results from these countries
would have had a disproportionate effect on overall
compliance (fig 1). Enrolment rates within centres dif-
fered across countries possibly because of heterogene-
ity in the nature of intensive care units and healthcare
systems.Previousdatahaveshownthattheprevalence
of infection in intensive care units is higher in those
countries that spend a smaller proportion of gross
domestic product on healthcare.
32 The inability of
many centres to measure lactate (fig 2) could also
have introduced selection bias as patients who would
have fulfilled criteria for severe sepsis based on hyper-
lactataemia, in the absence of other organ failures,
would not have been enrolled in these centres. While
selection bias is likely, we note that severe sepsis
accounted for 10.9% of all admissions to intensive
care units in our study, a rate that mirrors the 11%
seen in the United States
2 and Australia and New
Zealand.
33 The net effect of the selection bias could
be an overestimate of compliance with the Surviving
Sepsis Campaign bundles. With this in mind, and in
view of the heterogeneity of the study population, we
presented compliance rates stratified according to the
participatingcountries’WorldBankincomeclassifica-
tion to provide a clearer overview of sepsis manage-
ment in Asian countries.
According to the definitions of the Surviving Sepsis
Campaign,mere measurement of central venouspres-
sure, central or mixed venous oxygen saturation, and
Table 6 |Achievement of Surviving Sepsis Campaign bundle targets according to World Bank income classification of country. Figures are numbers of
patients (percentage, 95% confidence interval)
Target Low income countries Middle income countries High income countries P value
Resuscitation bundle (first 6 hours)
Measure lactate 25/176 (14.2, 9.0 to 19.4) 229/540 (42.4, 38.2 to 46.6) 257/569 (45.2, 43.7 to 51.9) <0.001*
Blood cultures before antibiotics 107/176 (60.8, 53.6 to 68.0) 281/540 (52.0, 47.8 to 56.3) 415/569 (72.9, 69.3 to 76.6) <0.001†
Broad spectrum antibiotics within 3 hours for ED admissions
and 1 hour for others
111/176 (63.1, 55.9 to 70.2) 335/540 (62.0, 58.0 to 66.1) 375/569 (65.9, 62.0 to 69.8) 0.40
Fluids with or without vasopressors 104/130 (80.0, 73.1 to 86.9) 340/410 (82.9, 79.3 to 86.6) 366/455 (80.4, 76.8 to 84.1) 0.58
CVP ≥8 mm Hg 38/118 (32.2, 23.8 to 40.6) 152/367 (41.4, 36.4 to 46.5) 155/385 (40.3, 35.4 to 45.2) 0.20
ScvO2 ≥70% or SvO2 ≥65% 8/118 (6.8, 2.2 to 11.3) 47/367 (12.8, 9.4 to 16.2) 39/385 (10.1, 7.1 to 13.1) 0.16
Management bundle (first 24 hours)
Low dose steroids considered or administered 78/116 (67.2, 58.7 to 75.8) 195/338 (57.7, 52.4 to 63.0) 176/351 (50.1, 44.9 to 55.4) 0.004‡
Drotrecogin alfa considered or administered 0/140 (0) 20/448 (4.5, 2.6 to 6.4) 14/463 (3.0, 1.5 to 4.6) 0.03§
Glucose ≥4.5 and ≤10.0 mmol/L at 6-24 hours 56/176 (31.8, 24.9 to 38.7) 141/540 (26.1, 22.4 to 29.8) 151/569 (26.5, 22.9 to 30.2) 0.31
Tidal volume ≤6 mL/kg PBW 10/101 (9.9, 4.1 to 15.7) 36/296 (12.2, 8.4 to 15.9) 28/233 (12.0, 7.8 to 16.2) 0.82
Overall compliance
Entire resuscitation bundle 4/176 (2.3, 0.1 to 4.5) 37/540 (6.9, 4.7 to 9.0) 57/569 (10.0, 7.6 to 12.5) 0.002¶
Entire management bundle 4/176 (2.3, 0.1 to 4.5) 25/540 (4.6, 2.9 to 6.4) 16/569 (2.8, 1.5 to 4.2) 0.16
CVP=central venous pressure; ED=emergency department; PBW=predicted body weight; ScvO2=central venous oxygen saturation; SvO2=mixed venous oxygen saturation.
*Target achieved more often in high v low income countries and in middle v low income countries.
†Target achieved more often in high v low income countries and in high v middle income countries.
‡Target achieved more often in low v high income countries.
§Target achieved more often in middle v low income countries.
¶Target for entire resuscitation bundle achieved more often in high v low income countries.
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Fig 3 | Proportion of emergency departments and intensive care units with protocols to achieve
individual bundle targets. Emergency departments not surveyed for steroids, drotrecogin alfa,
glucose measurements, and tidal volumes. CVP=central venous pressure; PBW=predicted body
weight; ScvO2=central venous oxygen saturation; SvO2=mixed venous oxygen saturation
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defined clinical targets are met.
3 While these targets
can easily be reached in mild disease, centres might
not achieve them and hence are deemed non-compli-
antinsickerpatients,notbecauseofafailuretoattempt
it but because of the sheer severity of illness. In
response, some investigators have recorded any
attempttomeasurecentralvenouspressureandcentral
or mixed venous oxygen saturation as being guideline
compliant, regardless of the values achieved.
1213 This
alternative method, however, does not necessarily
reflectanyattempttooptimisepreloadortissueoxyge-
nationand will probablyresult in anoverestimation of
compliancerates. This is illustratedby our data, which
show a largedifference between the frequencyof mea-
suring these parameters versus actual achievement of
clinical thresholds. As a result, we and others have
closely followed the campaign’s original definitions of
compliance.
31115
Other study limitations include the need to balance
comprehensive data collection versus simplicity
required to encourage participation. We omitted cul-
ture results as Asian microbiological data are already
available from a recent multinational study.
32 We
recorded tidal volumes instead of complex plateau
pressure measurements, choosing a threshold of
≤6 mL/kg of predicted body weight to define compli-
ance as per the Surviving Sepsis Campaign
recommendations.
925 Given the logistical difficulties
and questionable relevance of 28 day mortality,
34 like
other bundle studies,
1115 we recorded hospital mortal-
ity,whichisaffectedbyvariablethresholdsforhospital
discharge. Lastly, though we did not systematically
check data accuracy, we did design the online data
entry forms to disallow missing fields and contacted
intensive care unit representatives for clarification of
any outlying data.
Comparisons with other studies and implications
Overall compliance with the resuscitation (7.6%) and
management bundles (3.5%) was lower in our study
than in other multicentre cohorts.
11-15 Recent compli-
ance rates to adaptations of the resuscitation bundle
were 10.0% in Spain,
11 10.7% in France,
12 12.1% in
Portugal,
13and14%intheUnitedKingdom.
14Amulti-
national survey by the Surviving Sepsis Campaign,
which included countries in Europe and North and
South America, found a compliance rate of 31.3%.
15
Compliance rates with the management bundle were
15.7% in Spain,
11 and 36.1% in the multinational
survey.
15 Specifically, while compliance with those
bundle elements that we found were independently
associated with mortality (blood cultures, antibiotics,
and central venous pressure) was comparable with
that in other multicentre studies, achievement of indi-
vidual targets for glucose control (27.1%) and droteco-
gin alfa (3.2%) was poorer. Achievement of targets for
tidal volumes in acute lung injury/acute respiratory
distress syndrome was also lower in our study
(11.7%) than in a 2004 international survey that
included two Asian countries (19.6%).
35
Hospital mortality was 44.5% in our cohort, which
compares poorly with the 38% mortality reported in a
study from Australia and New Zealand, even after tak-
ing into account our slightly higher APACHE II score
(22.8 v 21).
36 Baseline mortality in a Spanish cohort
with a mean APACHE II score of 20.5 was 42.5%,
but improved to 38.7% after an educational pro-
grammedesignedtoincreasecompliancewiththesep-
sisbundles.
11InaFrenchcohortimprovedcompliance
withthebundleswasassociatedwithadecreaseinmor-
talityfrom39.6%to27.4%.
12Themultinationalsurvey
by the Surviving Sepsis Campaign showed a similar
reduction in mortality from 37% to 30.8% with
increased compliance.
15 Furthermore, a meta-analysis
ofeightsmallerstudiesfoundthatbundleusewasasso-
ciated with improved survival.
10 Taken together,these
Table 7 |Variables independently associated with hospital
mortality on logistic regression analysis in study of Surviving
Sepsis Campaign targets in patients admitted to Asian
intensive care units (ICU)
Variable*
Adjusted odds ratio
(95% CI) P value
Patients’ characteristics:
Age 0.98† (0.98 to 0.99) <0.001
APACHE II score 0.93‡ (0.92 to 0.95) <0.001
Location at diagnosis of severe sepsis:
ED v ward 0.68 (0.49 to 0.93) 0.01
ED v ICU 0.58 (0.40 to 0.83) 0.003
Achievement of bundle targets:
Blood cultures 0.72 (0.54 to 0.95) 0.02
Broad spectrum antibiotics 0.76 (0.58 to 0.99) 0.049
CVP ≥8 mm Hg 0.67 (0.47 to 0.94) 0.02
APACHE II=acute physiology and chronic health evaluation score during
first 24 hours of ICU admission; CVP=central venous pressure;
ED=emergency department.
*For model assessing blood culture, antibiotics, age, APACHE II score,
and location at diagnosis of severe sepsis, with Hosmer-Lemeshow test
for goodness of fit test, χ
2=11.434, df=8, P=0.18. For model assessing
CVP, χ
2=5.025, df=8, P=0.76.
†Per year decrease.
‡Per point decrease.
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compliance with the sepsis bundles in Asia.
Nonetheless, implementation of whole bundles
might be no more effective than implementation of
selected components. The only targets that were inde-
pendently associated with reduced mortality were
blood culture, antibiotics, and central venous pressure
inourstudyandbloodculture,antibiotics,drotrecogin
alfa, glucose control, and plateau pressure in the Sur-
viving Sepsis Campaign’s multinational study.
15
Indeed, concerns remain about the science behind
the sepsis bundles,
37 and prompt treatment with anti-
biotics is the only target that is consistently linked with
survival in multiple bundle studies.
101538 The use of
measurements of central venous pressure to guide
fluidresuscitationremainscontroversial.
39Ourfinding
that achieving a central venous pressure of ≥8m mH g
can improve survival does not necessarily mandate
such measurements but could suggest that aggressive
fluid resuscitation is often required in patients with
severe sepsis. Achievement of the target for fluids was
associated with decreased mortality on univariable
analysis, although fluids with or without vasopressors
were not linked with mortality on logistic regression
analysis. This could be because the latter target is a
composite of two dichotomous variables rather than
the exact volume of fluid administered. In our study,
although considered or administered more often in
non-survivors, steroids were not associated with mor-
tality on multivariable analysis, in keeping with the
findings of a large randomised controlled trial of corti-
costeroid treatment for septic shock.
22 The effective-
ness of other components of the bundles has also
been questioned, with another large randomised con-
trolled trial suggesting that intensive insulin treatment
could be harmful,
24 and ongoing studies are looking at
early goal directed treatment and drotrecogin alfa.
10
Despite these doubts, proponents of bundles might
advocate their implementation based on the premise
that the total is greater than the sum of the parts.
40
This premise would be supported by evidence of an
interaction between bundle components on logistic
regression, but we found no such interaction. Mean-
while, observational data that suggested a lower mor-
tality when whole bundles were fulfilled remain
confounded because it is easier to achieve all targets
in less sick patients.
101316
Concentrating on selected bundle targets might
therefore be required in resource constrained
Asia.
2030 Barriers to adherence to clinical practice
guidelines have been categorised into three areas:
knowledge, attitudes, and behaviour.
18 Although we
did not assess knowledge and attitudes, there are no
concerted national efforts to promote the sepsis bun-
dles in the countries participating in our study and a
lack of awareness might have affected compliance. In
addition clinicians’ behaviours are affected by the
availability of resources. Protocols alone are insuffi-
cient to ensure compliance. Full implementation of
the sepsis bundles is possible only with considerable
resources (see appendix 1 on bmj.com), which many
oftheparticipatingcentreslack.
41Compliancewiththe
resuscitation bundle was the lowest in low and middle
income economies, and Asia is home to some of the
world’s poorest nations.
30 Some emergency depart-
ments could not perform blood cultures or measure
central venous pressure or blood gases, and many
emergency departments and intensive care units
couldnotmeasurelactateandcentralormixedvenous
oxygen saturation. Drotrecogin alfa was not available
in participating intensive care units in nine countries.
We did not collect data on the availability of dobuta-
mine and blood, which could be required to optimise
central or mixed venous oxygen saturation, but it is
conceivable that these might also be in short supply
inpoorersettings.Insum,takingintoaccountselection
bias including the under-representation of the United
Nations’ Least Developed Countries and the over-
representation of university centres in our study, true
compliance to the sepsis bundles is likely to be even
lower than our data suggest. We suggest that given
the resource limitations in Asia, the most appropriate
strategy might be to focus on ensuring early adminis-
trationofantibioticsafterbloodculturesandappropri-
ate fluid treatment.
Conclusions
Compliance with the Surviving Sepsis Campaign’s
resuscitation and management bundles for severe sep-
sis in adult patients is generally poor in much of Asia.
Highincomecountriesandacademiccentresaremore
compliantwiththeresuscitationbundle.Mortalitywas
highinourcohort,suggestingthatmoreworkneedsto
be done to improve the outcome of severe sepsis in
Asia. Achievement of targets for blood cultures, anti-
biotics, and central venous pressure was indepen-
dently associated with improved survival. These
findings have important implications for healthcare
policy makers.
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